Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter.
暂无分享,去创建一个
D. Tindall | K. Slawin | X. Zhao | D. Spencer | C. Young | X. Xie | Y. Liu
[1] A. Pollack,et al. Prostate cancer gene therapy and the role of radiation. , 2002, Cancer treatment reviews.
[2] D. Tindall,et al. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. , 2000, Cancer research.
[3] P. Scardino,et al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. , 2000, The Journal of urology.
[4] R. Albertini,et al. Emergence of genetic instability in children treated for leukemia. , 2000, Science.
[5] N. James,et al. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. , 2000, Cancer research.
[6] T. Khan,et al. Improved artificial death switches based on caspases and FADD. , 1999, Human gene therapy.
[7] S. Weitzman,et al. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer , 1999, Gene Therapy.
[8] D. Tindall,et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. , 1999, Cancer research.
[9] D. Tindall,et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. , 1999, Urology.
[10] P. Scardino,et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. , 1999, Human gene therapy.
[11] D. Yu,et al. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. , 1999, Cancer research.
[12] H. Namba,et al. Retrovirus-Mediated Suicide Gene Prodrug Therapy Targeting Thyroid Carcinoma Using a Thyroid-Specific Promoter. , 1998, Endocrinology.
[13] P. Molloy,et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. , 1998, Human gene therapy.
[14] T. Miyamoto,et al. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. , 1998, The Journal of urology.
[15] D. Curiel,et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector , 1997, Nature Biotechnology.
[16] J. Simons,et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. , 1997, Cancer research.
[17] G G Klee,et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. , 1997, Urology.
[18] M. Kitamura,et al. Construction of adenovirus vectors through Cre-lox recombination , 1997, Journal of virology.
[19] J. Prieto,et al. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma. , 1997, Human gene therapy.
[20] D. Deperthes,et al. Short Communication Immunohistochemical Study Suggesting a Complementary Role of Kallikreins hK2 and hK3 (Prostate-Specific Antigen) in the Functional Analysis of Human Prostate Tumors , 2007 .
[21] H. Wakimoto,et al. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. , 1997, Cancer research.
[22] A. Belldegrun,et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. , 1997, Cancer research.
[23] S. McGuire,et al. Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. , 1996, Human gene therapy.
[24] J. D. Miller,et al. Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer (*) , 1996, The Journal of Biological Chemistry.
[25] J. Oesterling,et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. , 1995, Urology.
[26] R. Vile,et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. , 1994, Cancer research.
[27] S. Schreiber,et al. Controlling signal transduction with synthetic ligands. , 1993, Science.
[28] D. Tindall,et al. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. , 1993, Biochemistry.
[29] M. Gleave,et al. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. , 1993, Cancer research.
[30] M. Perricaudet,et al. An adenovirus vector for gene transfer into neurons and glia in the brain , 1993, Science.
[31] P. Riegman,et al. Characterization of the human kallikrein locus. , 1992, Genomics.
[32] Paolo Sassone-Corsi,et al. More is better: Activators and repressors from the same gene , 1992, Cell.
[33] D. Tindall,et al. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. , 1992, Biochemistry.
[34] Å. Lundwall. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. , 1989, Biochemical and biophysical research communications.
[35] G. Paradis,et al. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate‐specific antigen , 1988, FEBS letters.
[36] E. G. Erdös,et al. Molecular biology of tissue kallikrein. , 1988, The Biochemical journal.
[37] B. Morris,et al. Primary structure of a human glandular kallikrein gene. , 1987, DNA.